H.C. Wainwright analyst Boobalan Pachaiyappan lowered the firm’s price target on Gain Therapeutics to $9 from $10 and keeps a Buy rating on the shares. The analyst cites equity dilution for the target drop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GANX:
- Gain Therapeutics announces preclinical data on class of allosteric regulators
- Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
- Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
- Gain Therapeutics prices 2.2M shares at $2.005 in public offering
- Gain Therapeutics Announces Proposed Public Offering